Skip to main content
SpringerLink
Log in

Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice

  • Published:
Biotherapy

Abstract

This study shows that intraperitoneal injection of interleukin-1 (IL-1), followed by interleukin-2 (IL-2), can effectively eradicate murine ascitic tumor cells. This antitumor effect of IL-1 and IL-2 was abolished when administration of IL-2 preceded that of IL-1. Solid tumors inoculated subcutaneously (s.c.) into the back of mice were also sensitive to this combined i.p. therapy, indicating a systemically-operating antitumor mechanism. Splenocytes from tumor-bearing mice treated with IL-1 followed by IL-2 showed a strong tumor-neutralizing activity. The population responsible proved to be Lyt2.2 (CD8)-positive cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

IL:

interleukin

LAK:

lymphokine activated killer

LU:

lytic unit

MST:

median survival time

SE:

sonicated tumor extract

References

  1. Bubenik J. Local immunotherapy of cancer with interleukin-2. Immunol Lett 1989; 21: 267–73.

    PubMed  Google Scholar 

  2. Ciolli V, Gabriele L, Sestili P, Varano F, Proietti E, Gresser I, Testa U, Montesoro E, Bulgarini D, Mariani G, Peschle C, Belardelli F. Combined interleukin 1/interleukin 2 therapy of mice injected with highly metastatic friend leukemia cells: Host antitumor mechanisms and marked effects on established metastases. J Exp Med 1991; 173: 313–22.

    PubMed  Google Scholar 

  3. Cramp III WL, Owen-Schaub LB, Grimm EA. Synergy of human recombinant interleukin 1 with interleukin 2 in the generation of lymphokine-activated killer cells. Cancer Res 1989; 49: 149–53

    PubMed  Google Scholar 

  4. Dinarello CA. Interleukin 1. Rev Infect Dis 1984; 6: 51–95

    PubMed  Google Scholar 

  5. Dinarello CA. Interleukin-1 and its biologically related cytokines. Adv Immunol 1989; 44: 153–205

    PubMed  Google Scholar 

  6. Ebina T, Murata K. Anti tumor effector mechanism of interleukin-1β at a distant site in the double grafted tumor system. Jpn J Cancer Res 1991; 82: 1292–98

    PubMed  Google Scholar 

  7. Gillis S, Smith AK, Watson J. Biochemical characterization of lymphocyte regulatory molecules. II. Purification of a class of rat and human lymphokines. J Immunol 1980; 124: 1954–62

    PubMed  Google Scholar 

  8. Iigo M, Sakurai M, Tamura T, Saijo N, Hoshi A. In vivo anti tumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon on various syngeneic murine tumors. Cancer Res 1988; 48: 260–64

    PubMed  Google Scholar 

  9. Izumi Y, Tsuchida T, Okuno K, Fujiwara H, Hamaoka T. Enhanced induction of tumor-specific Lyt1+2−T cell-mediated protective immunity by in vivo administration of interleukin 1. Jpn J Cancer Res 1985; 76: 863–70

    PubMed  Google Scholar 

  10. Kamogashira T, Masui Y, Ohmoto Y, Hirano T, Nagamura K, Mizuno K, Hong YM, Kikumoto Y, Nakai S, Hirai Y. Site-specific mutagenesis of the human interleukin-1β gene: Structure-function analysis of the cysteine residues. Biochem Biophys Res Commun 1988; 150: 1106–14

    PubMed  Google Scholar 

  11. Kan N, Ohgaki K, Inamoto T, Kodama H. Antitumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 1984; 18: 215–22

    PubMed  Google Scholar 

  12. Kato K, Yamada T, Kawahara K, Onda H, Asano T, Sugini H, Kakinuma A. Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli. Biochem Biophys Res Commun 1985; 130: 692–99

    PubMed  Google Scholar 

  13. Kuribayashi K, Gillis S, Kern ED, Henney SC. Murine NK cell cultures: Effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 1981; 126: 2321–27

    PubMed  Google Scholar 

  14. Lotze M, Grimm EA, Mazumber A, Strausser JL, Rosenberg SA. Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res 1981; 41:4420–25

    PubMed  Google Scholar 

  15. McIntosh JK, Mulé JJ, Merino MJ, Rosenberg SA. Synergistic antitumor effects of immunotherapy with recombinant interleukin-2 and recombinant tumor necrosis factor-alpha. Cancer Res 1988; 48: 4011–17

    PubMed  Google Scholar 

  16. Nakamura S, Nakata K, Kashimoto S, Yoshida H, Yamada M. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors. Jpn J Cancer Res 1986; 77: 767–73

    PubMed  Google Scholar 

  17. North RJ, Neubauer RH, Haung JJH, Newton RC, Loveless SE. Interleukin 1-induced, T cell mediated regression of immunogenic murine tumors. J Exp Med 1988; 167: 2031–43

    Google Scholar 

  18. Onozaki K, Matsushima K, Kleinerman ES, Saito T, Oppenheim JJ. Role of interleukin 1 in promoting human monocytemediated tumor cytotoxicity. J Immunol 1985; 135: 314–20

    PubMed  Google Scholar 

  19. Onozaki K, Matsushima K, Aggarwal BB, Oppenheim JJ. Human interleukin 1 is a cytocidal factor for several tumor cell lines. J Immunol 1985; 135: 3962–68

    PubMed  Google Scholar 

  20. Oppenheim JJ, Kovacs EJ, Matsushima K, Durum SK. There is more than one interleukin 1. Immunol Today 1986; 7: 45–56

    Google Scholar 

  21. Papa MZ, Mulé JJ, Rosenberg SA. Anti tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: Successful immunotherapy of established pulmonary metastases from weakly immunogenic and nonimmunogenic murine tumors of three distinct histological types. Cancer 1986; 46: 4973–78

    Google Scholar 

  22. Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg 1985; 210: 474–85

    Google Scholar 

  23. Silagi S, Dutkowski R, Schaefer A. Eradication of mouse melanoma by combined treatment with recombinant human interleukin 2 and recombinant murine interferon-gamma. Int J Cancer 1988; 41: 315–22

    PubMed  Google Scholar 

  24. West WH, Tauer KW, Yanelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin 2 in adoptive immunotherapy of advanced cancer. N Ingl J Med 1978; 316: 898–905

    Google Scholar 

  25. Winkelhake JL, Stampfl S, Zimmerman RJ. Synergistic effects of combination therapy with human recombinant interleukin-2 and tumor necrosis factor in murine tumor models. Cancer Res 1987; 47: 3948–53

    PubMed  Google Scholar 

  26. Winn HJ. Immune mechanisms in homotransplantation. II. Quantitative assay of the immunologic activity of lymphoid cells stimulated by tumor homograft. J Immunol 1961; 86: 228–39

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Laboratory of Oncologic Surgery, First Department of Surgery, Faculty of Medicine, Kyoto University, Japan

    Takehisa Harada, Norimichi Kan, Takashi Okino, You Ichinose, Yoshio Moriguchi, Li Li, Tomoharu Sugie, Kazuhisa Ohgaki & Masayuki Imamura

Authors
  1. Takehisa Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Norimichi Kan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Takashi Okino
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. You Ichinose
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yoshio Moriguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Li Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Tomoharu Sugie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazuhisa Ohgaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Masayuki Imamura
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Harada, T., Kan, N., Okino, T. et al. Sequential immunotherapy using interleukin-1 followed by interleukin-2 of ascitic MOPC104E-bearing mice. Biotherapy 7, 91–99 (1993). https://doi.org/10.1007/BF01877732

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01877732

Key words

Search

Navigation